BioAge Labs, Inc. (BIOA) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$7.92

From 52W high−67.89%

Volume1.48M

Market cap$369.93M

P/E (TTM)—

P/S (TTM)35.7x

Div yield—

Key dataSep 18, 2026

Open

$7.92

From 52W high

−67.89%

Volume

1.48M

Market cap

$369.93M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.6x

P/E (TTM)

—

RSI (14)

29.2

MomentumView details →

1D Return

−0.37%

YTD Return

−40.03%

SummaryUpdated Jun 1, 2026

BioAge Labs, Inc. (NASDAQ:BIOA) is a clinical-stage biopharmaceutical company founded in 2015 and based in Richmond, California. The company went public in September 2024, marking its transition from a private research entity to a publicly traded biotechnology firm. BioAge specializes in developing therapeutic treatments for metabolic diseases by leveraging insights into the molecular mechanisms of aging. The company's approach centers on understanding how aging processes contribute to various health conditions, particularly focusing on obesity and neuroinflammation-related disorders.

Ask drillr about BioAge Labs, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.6x

EV/Sales

5.2x

P/S (TTM)

35.7x

P/B (TTM)

1.0x

ProfitabilityView details →

Gross Margin

99.39%

Net Margin

−912.25%

EBITDA Margin

−907.12%

ROE (TTM)

−25.20%

ROA (TTM)

−23.80%

Asset Turnover

0.03x

GrowthView details →

Revenue YoY

+168.06%

EPS YoY

+75.29%

FCF YoY

−51.05%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−13.13%

EBITDA YoY

−20.92%

MomentumView details →

1D Return

−0.37%

YTD Return

−40.03%

1Y Return

+61.93%

RSI (14)

29.2

vs 50D SMA

−41.61%

vs 200D SMA

−53.08%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

17.19x

Quick Ratio

17.19x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.58

EPS Surprise

4.50%

Beats (12Q)

4/12

Next Q EPS Est

−$0.62

Avg Surprise (4Q)

13.22%

Rev Surprise

63.65%

Financials snapshotView financials →

Revenue (TTM)

10.36M

Net Income (TTM)

−94.46M

Op. CF (TTM)

−87.60M

Next earningsNov 5, 2026 →

Latest newsMore news →

BioAge Labs dosed the first participant in QUELL-DME, a Phase 2 trial of oral BGE-102 for diabetic macular edema, with topline results expected in the second half of 2027.12d ago

Dimensional Fund Advisors LP acquired a new position of 214,546 shares in BioAge Labs, Inc. during the first quarter, valued at approximately $3,746,000, as disclosed in its Form 13F filing.38d ago

Similar companies

Rocket Pharmaceuticals, Inc.RCKT Rezolute, Inc.RZLT DiaMedica Therapeutics Inc.DMAC Fennec Pharmaceuticals Inc.FENC Orchestra BioMed Holdings, Inc.OBIO Ocugen, Inc.OCGN Find similar companies →

Latest newsMore news →

BioAge Labs dosed the first participant in QUELL-DME, a Phase 2 trial of oral BGE-102 for diabetic macular edema, with topline results expected in the second half of 2027.12d ago Dimensional Fund Advisors LP acquired a new position of 214,546 shares in BioAge Labs, Inc. during the first quarter, valued at approximately $3,746,000, as disclosed in its Form 13F filing.38d ago